MacroChem Corp. (fka MACM)

[jscot]

Outstanding at August 14, 2008:



45,798,412

[INDY]

MACM Chart

[OptionMonster]

O/S increased about 19 Million quarter over quarter..Outstanding at November 2, 2007: 22,461,997

[xZx]

i agree, this is quite encouraging. :)

[Paulness]

Nice news today , can we all say buy out , bought 1,300 more shares today , I keep on adding . Good luck to all stock holders.

David Luci Joins MacroChem as General Counsel and Vice President Corporate Development
Luci Brings Successful Track Record of Building Value in Biotech Arena Through Experience in Business Development and Investment Community Outreach
WELLESLEY HILLS, Mass., Dec. 6 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) has appointed David P. Luci, Esq. as General Counsel and Vice President Corporate Development. Mr. Luci will also be Corporate Secretary with responsibilities encompassing all the company's legal matters including compliance with securities regulations and corporate governance. Included in the scope of Corporate Development activities will be responsibility for partnering activities and investor relations.

'I'm very pleased to welcome David to MacroChem. Having recently completed three very important milestones, we are confident that David's extensive experience will help bolster the company's continued momentum,' stated Robert DeLuccia, President and CEO of MacroChem. 'These key milestones are: last month's announcement of positive interim Phase 2 data for EcoNail(R) for the treatment of onychomycosis; the recent acquisition of exclusive worldwide license rights to pexiganan, a novel topical anti-infective peptide for the treatment of diabetic foot infection, which has already completed two Phase 3 trials; and the recent conversion of all preferred shares into common shares leaving only common stock, warrants, and options outstanding.'

Most recently, Mr. Luci served as Executive Vice President and General Counsel of Bioenvision where he established the company's offices in New York, raised over $75 million in capital, and advanced Bioenvision stock listing from OTCBB to AMEX and then to NASDAQ. He was also responsible for garnering analyst interest for a number of investment firms. While at Bioenvision, he in-licensed the company's development-stage lead cancer drug for Japan and Southeast Asia and initiated drug development activities in Japan. He later successfully guided Bioenvision into a merger agreement and closing of a related tender offer with its U.S. co-development partner, Genzyme, in a transaction valued at approximately $345 million. Prior to joining Bioenvision, Mr. Luci practiced securities law and mergers and acquisitions at Paul, Hastings, Janofsky and Walker LLP, New York. Prior to PHJW, he was Senior Auditor, Ernst and Young, New York, focused on internal audit and controls within the Mergers and Acquisitions Practice Group. He is also a member of the Board of Directors and Chairman of the Audit Committee of Access Pharmaceuticals, Inc.

'David brings a diverse legal, financial, and business background as well as excellent knowledge of the biotech sector, both with pharmaceutical companies and the investment community of our industry,' said Mr. DeLuccia. 'His experience includes capital markets financing, negotiating deals, and license agreements (both U.S. and ex-U.S.), corporate partnerships, and mergers and acquisitions. I believe this impressive skill set will serve us well as we seek to capitalize on our recent achievements and advance our initiatives in the coming year.'

Mr. Luci received his JD, cum laude, from Albany Law School of Union University, Albany, and his Bachelor of Science in Business Administration from Bucknell University. He is a member of the New York Bar Association and a Certified Public Accountant (Pennsylvania).

[OptionMonster]

No problem Brikk!

[xZx]

progress. :) thanks for posting this. not sure why, but i didn't catch this on my news streamer today.

[OptionMonster]

MacroChem Announces Positive Interim Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
54% of patients showed clinical improvement after 24 weeks of once-daily treatment; no skin irritation observed
WELLESLEY HILLS, Mass., Nov. 6 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) (www.macrochem.com) today announced positive interim Phase 2 data for patients who completed 24-weeks of treatment in an ongoing 48-week, U.S. multi-center open-label efficacy study of EcoNail, a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). EcoNail is the company's patented lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA(R).

A protocol-mandated, external expert panel assessed clinical photographs of 37 onychomycosis patients who completed 24 weeks of EcoNail treatment, and 20 (54%) showed evidence of clinical improvement, defined as an increase in uninvolved nail area. At week 24, 100% of patients had cultures that were negative for dermatophyte growth. The panel observed no signs of local irritation related to the once-daily EcoNail treatment. In the judgment of the panel, the consensus was that 12 of 37 (32%) patients demonstrated significant (greater than or equal to 25%) clinical improvement.

Mycologic cultures for this trial were performed in the laboratory of Boni Elewski, MD, Professor of Dermatology at University of Alabama-Birmingham. According to Dr Elewski, 'The negative dermatophyte cultures, coupled with the overall clinical improvement observed, suggests the promise of this new treatment for a very common and difficult-to-cure condition. Onychomycosis is a progressive infection in which fungal involvement often spreads; however, in this study, I was particularly impressed that the fungal burden was reduced. We look forward to the completion of this Phase 2 trial, and to future definitive efficacy trials.'

Michael Goldfarb, MD, Attending Physician, Department of Dermatology at the University of Michigan, who assisted MacroChem in the development of the protocol, added: 'In a field where clinical trials are challenging, from both an operational and a regulatory perspective, this study is producing an exemplary dataset. The clinical improvement observed so far in this patient population, especially in some individuals, impressed me as a practitioner who has limited options, whether oral or topical, to offer patients with onychomycosis. The absence of clinical signs of local irritation is especially notable in light of the high need for safe, as well as effective, topical treatments in this field.'

'We feel this trial is as robust a Phase 2 study as has been performed in this field', stated Robert DeLuccia, President and CEO of MacroChem. He continued, 'Its design and conduct includes the use of onychomycosis experts as investigators at US sites, strict enrollment criteria with all patients required to be fungal-culture positive at entry, the use of registration-type primary endpoints and treatment duration, monthly photographs for documentation, and the innovative use of an external expert panel to review clinical data, all of which give us confidence in the anticipated results from this study when completed, and in the reproducibility of data in the Phase 3 program currently envisioned. Additionally, I am extremely pleased to note the lack of observed skin irritation.'

DeLuccia further noted, 'These positive interim results are an important milestone for our Company and very encouraging as we look forward to completing the full study next year.' He continued, 'I believe that the recent precedent-setting deal activity for topical nail fungus products in clinical development by two major international pharmaceutical companies reflects the high level of interest and commercial opportunity in the marketplace for new treatments for onychomycosis. With these data we will step-up our partnering discussions for the next phase of clinical development.'

About the EcoNail Phase 2 trial and Onychomycosis

Patients participating in the EcoNail study, which is being conducted under MacroChem's U.S. Investigational New Drug application filed with the FDA, will receive 48 weeks of treatment at U.S. sites and will undergo efficacy assessments using standard criteria of nail appearance and mycology. This trial was specifically designed, with the assistance of well-known onychomycosis experts, to address three important objectives: to assess early signs of efficacy, to maintain robust clinical endpoints in the full study, and, if successful, to facilitate advancement to Phase 3 as soon as possible.

Onychomycosis affects 20-30 million people in the United States alone, including nearly half of those over age 70. Untreated, the disease causes nails to thicken, resulting in localized pressure-related pain. Topical treatments currently marketed in the U.S. reportedly succeed in fewer than 12 percent of patients, and existing systemic treatments, which are effective in less than half of all cases, have known toxicity. Despite the shortcomings of these existing drugs, sales of treatments for onychomycosis top $1.5 billion annually worldwide.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled 'Risk Factors' in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, www.macrochem.com.

Contact:
MacroChem: Bernard Patriacca - VP/CFO
[e-mail]
[phone]
Investor Relations: The Investor Relations Group, Inc.
Christine Berni/ Joseph Triunfo, [phone]
[e-mail]
[e-mail]
Media:
Bill Douglass/ Michaela Heller, [phone]
[e-mail]
[e-mail]

SOURCE MacroChem Corporation



Source: PR Newswire (November 6, 2007 - 8:04 AM EST)

News by QuoteMedia
www.quotemedia.com

[dl_bones]

Good morning y'all!

[dl_bones]

Yes sir it was!!! :)

[OptionMonster]

Another nice day here to bro!!$$

[dl_bones]

HHHMMMM, interesting!

[OptionMonster]

MacroChem CEO to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference November 6, 2007 in New York City
WELLESLEY HILLS, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Robert J. DeLuccia, President and CEO of MacroChem (OTC Bulletin Board: MACM) (http://www.macrochem.com), will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference being held in NYC from Nov 5-7. Mr. DeLuccia will present on November 6, 2007 at 10:15AM ET in the Hubbard Room at the New York Palace Hotel. He will provide a company overview including its two priority product candidates: EcoNail(R), which is currently in a fully enrolled Phase 2 efficacy trial, and pexiganan, the Company's recently acquired novel topical anti-infective drug for treatment of diabetic foot infection (DFI).

The Conference will include presentations by over 350 companies, as well as experts from the medical, scientific, and investment communities. The conference is attended by investors, venture capitalists, company executives, scientists, and other industry leaders.

A live audio webcast of this presentation can be accessed via http://www.wsw.com/webcast/rrshq12/macm.ob.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA(R)-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled 'Risk Factors' in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.

Contact:
MacroChem: Bernard Patriacca - VP/CFO
[e-mail], [phone]
Investor Relations: The Investor Relations Group, Inc.
Christine Berni/ Joseph Triunfo, [phone]
[e-mail], [e-mail]
Media:
Bill Douglass/ Michaela Heller, [phone]
[e-mail], [e-mail]

SOURCE MacroChem



Source: PR Newswire (October 30, 2007 - 10:03 AM EDT)

News by QuoteMedia
www.quotemedia.com

[xZx]

good morning!

[dl_bones]

Good morning y'all!

[mo-rydr]

Just ran into it while looking for something else. Can you tell me what this means for you guys?

[OptionMonster]

Thanks mo!

[mo-rydr]

8-K out

http://biz.yahoo.com/e/071010/macm.ob8-k.html

[xZx]

the warrants have an exercise price of .60...

[dl_bones]

LOL, Yeah, I dont get it either.

[dl_bones]

Done! :)

[OptionMonster]

News and we go down..Gotta love it!

[dl_bones]

You know that at least take me a month to do.................

LOL, working on it now.

[OptionMonster]

Nice! Get that puppy in the I-Box..lol

[dl_bones]

NEW PR!

MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement
Wednesday October 10, 8:00 am ET


WELLESLEY HILLS, Mass., Oct. 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM - News) announced today that all the holders of its Series C Preferred Stock have converted their shares of preferred stock into 12,571,850 shares of common stock, and the warrants to purchase 8,648,102 shares of common stock previously issued with the Series C Preferred Stock have been reset to purchase 17,885,848 shares with an exercise price of $.60 per share pursuant to anti-dilution provisions in the warrants. In connection with the transaction, the Company closed a private placement of $3.5 million in gross proceeds, issuing 5,891,667 shares of common stock and five-year warrants to purchase 1,767,500 shares of common stock exercisable at $.60 per share. Griffin Securities, Inc. acted as placement agent in connection with the private placement.
ADVERTISEMENT


"We're pleased with the support and confidence of our shareholders and new investors participating in this transaction," stated Robert J. DeLuccia, President and Chief Executive Officer of MacroChem. "We believe this transaction will simplify our capital structure by leaving only common stock, warrants and options outstanding, enable us to continue advancing EcoNail® through its Phase 2 clinical program and initiate development work on our newly acquired product, pexiganan, which has already completed two Phase 3 trials."

The securities offered and sold to the investors in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act") and were sold in reliance upon the exemption from securities registration afforded by Regulation D under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone®, is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA®, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com .

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com .

[xZx]

ah, i see it now. thanks! well -- i'm not thinking about the chart here much at all. what about that flurry of recent PRs? seems to me like they've got some nice activity going on the corporate side. imo this should translate into some stock price momentum pretty soon. i'm just accumulating here for the move over a buck.

[OptionMonster]

Sorry Brikk..Put the wrong link in http://quotes.barchart.com/texadv.asp?sym=macm

[xZx]

i'm sorry -- what's this link for?

[OptionMonster]

http://investorshub.advfn.com/boards/favorites.asp

[dl_bones]

Up .10 today! :)

[xZx]

agreed. i grabbed a little bit more. seems like they've got some activity going on behind the scenes, doesn't it? i doubt this PR is the last we'll hear in terms of new developments for MACM.

[Paulness]

Nice news today

MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Broadens late-stage product development portfolio building on lead product candidate EcoNail in Phase 2 trial for onychomycosis
WELLESLEY HILLS, Mass., Oct. 3 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced that it has exercised the option it acquired in July, 2007 to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation.

'We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials and that fits our strategic focus and complements our lead product candidate, EcoNail(R) for treatment of nail fungus,' stated Robert J. DeLuccia, President and CEO of MacroChem. 'Both drugs would treat diseases of the foot predominantly treated by the same prescribing specialists, namely podiatrists. Both EcoNail and pexiganan are potentially of interest to a larger number of physician specialists and primary care physicians. MacroChem would ultimately be seeking a partner for marketing to those groups while retaining rights to market to selected physician specialists

[Paulness]

This is the only stock I have ever bought with such a low float , if no new shares hits the market, and very good news hits the wire we will all be in a very good solid financial condition very quickly .

[xZx]

it's got a history of roller coaster thrills, that's for sure. :O

[Paulness]

WOW , glad I bought in ,this could easily hit $5.00 with some good news . Very low float.

[xZx]

looking good. :)

[OptionMonster]

Up another 18 so far today..Can you say something is brewing here?

[xZx]

yes, very nice. i was watching it all day hoping MACM would pull back a little for an add -- just kept going. i'm betting next week is good. :)

[OptionMonster]

Up 14 cents today!! WOW$$$

[dl_bones]

Man it did!

[OptionMonster]

Took a 6 cent beating today..lol

[dl_bones]

She's working her way down a little. Almost primed for action!

[OptionMonster]

Dang! Lost a penny today!

[dl_bones]

LOL, got to. Just a matter of time, folks will start taking notice of this company.

[xZx]

:) gotta love it.

[OptionMonster]

Talk about a MONSTER volume day!!

[dl_bones]

VERY NICE!

[dl_bones]

I know, it's nuts!!

[OptionMonster]

No gaps just needs volume .55 support , consolidation at .62 as long as no sellers come into play , you need to break and hold the 200MA at .64 for bullish trend to be in effect

[OptionMonster]

lol